natriuretic-peptide--brain and Noonan-Syndrome

natriuretic-peptide--brain has been researched along with Noonan-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for natriuretic-peptide--brain and Noonan-Syndrome

Article	Year
Mek Inhibitor Reverses Hypertrophic Cardiomyopathy in RIT1 Mutated Noonan Syndrome: For the first time, hypertrophic cardiomyopathy was reversed in Noonan syndrome associated with a RIT1 mutation. American journal of medical genetics. Part A, 2019, Volume: 179, Issue:8 Topics: Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Drug Repositioning; Echocardiography; Gene Expression Regulation; Heart Valves; Heterozygote; Humans; Infant; MAP Kinase Kinase 1; Mutation; Natriuretic Peptide, Brain; Noonan Syndrome; Peptide Fragments; Propranolol; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ras Proteins; Signal Transduction; Treatment Outcome	2019
Apicoaortic conduit for the dilated phase of hypertrophic obstructive cardiomyopathy as an alternative to heart transplantation. Interactive cardiovascular and thoracic surgery, 2009, Volume: 8, Issue:2 We describe a 16-year-old suffering from the dilated phase of mid-ventricular obstructive hypertrophic cardiomyopathy with end-stage heart failure. Her plasma type-B natriuretic peptide level exceeded 8000 pg/ml, and she refused heart transplantation. She underwent an apicoaortic valved conduit as an alternative to the heart transplant procedure. This traditional procedure is still an ideal operation for very sick cardiomyopathy patients to avoid or delay heart transplantation. Topics: Adolescent; Biomarkers; Cardiac Surgical Procedures; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Heart Failure; Heart Transplantation; Humans; Natriuretic Peptide, Brain; Noonan Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Up-Regulation	2009

Article

Year

Mek Inhibitor Reverses Hypertrophic Cardiomyopathy in RIT1 Mutated Noonan Syndrome: For the first time, hypertrophic cardiomyopathy was reversed in Noonan syndrome associated with a RIT1 mutation.

American journal of medical genetics. Part A, 2019, Volume: 179, Issue:8

Topics: Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Drug Repositioning; Echocardiography; Gene Expression Regulation; Heart Valves; Heterozygote; Humans; Infant; MAP Kinase Kinase 1; Mutation; Natriuretic Peptide, Brain; Noonan Syndrome; Peptide Fragments; Propranolol; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ras Proteins; Signal Transduction; Treatment Outcome

2019

Apicoaortic conduit for the dilated phase of hypertrophic obstructive cardiomyopathy as an alternative to heart transplantation.

Interactive cardiovascular and thoracic surgery, 2009, Volume: 8, Issue:2

We describe a 16-year-old suffering from the dilated phase of mid-ventricular obstructive hypertrophic cardiomyopathy with end-stage heart failure. Her plasma type-B natriuretic peptide level exceeded 8000 pg/ml, and she refused heart transplantation. She underwent an apicoaortic valved conduit as an alternative to the heart transplant procedure. This traditional procedure is still an ideal operation for very sick cardiomyopathy patients to avoid or delay heart transplantation.

Topics: Adolescent; Biomarkers; Cardiac Surgical Procedures; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Heart Failure; Heart Transplantation; Humans; Natriuretic Peptide, Brain; Noonan Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Up-Regulation

2009